DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pureum Lee | - |
dc.contributor.author | Chang-Ung Kim | - |
dc.contributor.author | S H Seo | - |
dc.contributor.author | Doo-Jin Kim | - |
dc.date.accessioned | 2021-03-19T03:30:26Z | - |
dc.date.available | 2021-03-19T03:30:26Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 1598-2629 | - |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/24190 | - |
dc.description.abstract | The global outbreak of coronavirus disease 2019 (COVID-19) is still threatening human health, economy, and social life worldwide. As a counteraction for this devastating disease, a number of vaccines are being developed with unprecedented speed combined with new technologies. As COVID-19 vaccines are being developed in the absence of a licensed human coronavirus vaccine, there remain further questions regarding the long-term efficacy and safety of the vaccines, as well as immunological mechanisms in depth. This review article discusses the current status of COVID-19 vaccine development, mainly focusing on antigen design, clinical trials in later stages, and immunological considerations for further study. | - |
dc.publisher | Korea Soc-Assoc-Inst | - |
dc.title | Current status of COVID-19 vaccine development: focusing on antigen design and clinical trials on later stages | - |
dc.title.alternative | Current status of COVID-19 vaccine development: focusing on antigen design and clinical trials on later stages | - |
dc.type | Article | - |
dc.citation.title | Immune Network | - |
dc.citation.number | 1 | - |
dc.citation.endPage | e4 | - |
dc.citation.startPage | e4 | - |
dc.citation.volume | 21 | - |
dc.contributor.affiliatedAuthor | Pureum Lee | - |
dc.contributor.affiliatedAuthor | Chang-Ung Kim | - |
dc.contributor.affiliatedAuthor | Doo-Jin Kim | - |
dc.contributor.alternativeName | 이푸름 | - |
dc.contributor.alternativeName | 김창웅 | - |
dc.contributor.alternativeName | 서상환 | - |
dc.contributor.alternativeName | 김두진 | - |
dc.identifier.bibliographicCitation | Immune Network, vol. 21, no. 1, pp. e4-e4 | - |
dc.identifier.doi | 10.4110/in.2021.21.e4 | - |
dc.subject.keyword | COVID-19 | - |
dc.subject.keyword | Vaccines | - |
dc.subject.keyword | Prefusion-stabilized | - |
dc.subject.keyword | VAERD | - |
dc.subject.keyword | Antibody-dependent enhancement | - |
dc.subject.keyword | Pre-existing immunological memory | - |
dc.subject.local | COVID-19 | - |
dc.subject.local | Covid19 | - |
dc.subject.local | COVID19 | - |
dc.subject.local | CCOVID 19 | - |
dc.subject.local | COVID?19 | - |
dc.subject.local | Vaccines | - |
dc.subject.local | Prefusion-stabilized | - |
dc.subject.local | VAERD | - |
dc.subject.local | Antibody-dependent enhancement | - |
dc.subject.local | Pre-existing immunological memory | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.